A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

Guselkumab shows rapid and significant scalp psoriasis clearance in patients with skin of color, according to a press release by Johnson & Johnson.. Researchers presented topline results from ...

The anti-interleukin-23 monoclonal antibody guselkumab performed significantly better than the anti-tumor necrosis factor therapy adalimumab in the treatment of plaque psoriasis. The results of ...

Gracia Cazaña T, Riera Monroig J, Izu R, et al. Real-world outcomes in patients with malignancy and moderate-severe psoriasis treated with guselkumab. JAAD International.

Long-term use of guselkumab in the treatment of psoriasis does not yield increased cancer rates compared with the general and psoriasis populations, according to a study.“Safety of biologic ...

Guselkumab significantly improved skin clearance and quality of life in patients with moderate-to-severe psoriasis who self-identify as belonging to a racial or ethnic category other than White in ...

In patients with early and complete clearance of psoriasis, extending the guselkumab dosing interval to every 16 weeks maintained disease control as well as an 8-week interval, according to a ...

Guselkumab Demonstrates Lasting Benefits in Plaque Psoriasis Patients, According to 4-Year Data. ... and 12 followed by crossover to guselkumab 100mg at weeks 16 and 20 then every 8-weeks ...

Guselkumab is currently marketed under the brand name Tremfya ® and is approved for the treatment of active psoriatic arthritis and moderate to severe plaque psoriasis in adults who are ...